Trulieve Grew Revenue 4% and Shrank It 15% — Both Numbers Are True
A Schedule III makeover, a brand portfolio that suddenly owns the keyword list, and a Texas license that has been 'imminent' for two straight quarters
TRLV · Earnings Call · 2026-11-05
The Optical Collapse That Isn't One
Any screen run on Trulieve this morning will show a company whose revenue went backwards 15% sequentially — from $271 million in the last filed quarter to $230 million for the September period. That is a deconsolidation artifact, not a demand signal. Harvest is now an equity investment rather than a consolidated subsidiary, and the last 10-Q on file is the messy consolidated version of the business — the one that printed an operating loss of $383 million and a net loss of $406 million, a quarter that will never repeat in this form.
The clean comparison is the one the CFO put on the table: “Third quarter medical revenue was $230 million compared to medical only revenue of $221 million in Q3 last year and $222 million in Q2 this year.” — Jan Reese, Chief Financial Officer · 2026-11-05 That is +4% on both axes — against a Florida market in its normal seasonal trough. Gross margin came in at 64%, adjusted EBITDA at $89 million (39% margin), and the CEO opened with the line that “third quarter results that exceeded guidance with higher revenue, margins and cash generation.” — Kimberly Rivers, Chief Executive Officer · 2026-11-05 The balance sheet has swung hard: from effective net cash of negative $68 million in 2024Q4 to positive $125 million, and management ended Q3 with $327 million of cash against $289 million of debt, before retiring a $65 million mortgage in October.
So the reported numbers scream distress while the operating numbers whisper competence. The gap between those two readings is the entire setup.
What the Keyword List Says Actually Changed
The most revealing thing about this quarter is not in the P&L — it is in what management chose to talk about. A quarter ago the company's keyword profile led with Medical Marijuana, independent pharmacy, hemp market, conditional license and deconsolidation — a regulatory-and-accounting conversation. This quarter's list is a merchandising conversation: Alien Labs, Roll 1, Modern Flower, house brands, customer retention, rewards program. Top of the list is state licensed, the legal architecture that now permits all of it.
The September master licensing deal with Connected — perpetual royalty-free rights to Alien Labs genetics and trademarks in Florida and Texas, with a stated payback under two years — is the new strategic object. The CEO framed the logic around owning a brand at every price tier: “it is our goal to have a strengthened brand at each tier of customer across the platform.” — Kimberly Rivers, Chief Executive Officer · 2026-11-05 Retention at 75%, a rewards base past 700,000 members spending 2.1x non-members and driving over 80% of transactions, an app handling 30% of online orders — that is a consumer-packaged-goods story wearing a cannabis wrapper.
And then there is what disappeared. Last quarter the hemp market was the single most quantified upside on the call:
The regulated medical marijuana market in Florida is about $2 billion. And the hemp market in Florida, we would estimate to be about $4 billion.
A $4 billion addressable pool, roughly twice the size of the regulated market, with a federal ban scheduled to force conversion. This quarter it survives as a single clause in the closing remarks — “potential conversion of customers, from the intoxicating hemp market, once the federal ban takes effect next month” — Kimberly Rivers, Chief Executive Officer · 2026-11-05 — and no analyst asked a single question about it. When the most concrete catalyst from one call becomes a subordinate clause in the next, that is a signal, and it is not a bullish one about near-term visibility.
The Tax Option Nobody Is Pricing
Buried in the CFO's tax section is the largest un-modeled asset in the story. Trulieve's balance sheet carries an uncertain tax position that includes Ordinary taxes, the 280E liability, more than $102 million of refunds already received from the IRS, and accrued interest — including $18 million of interest in a single quarter. Reported tax expense no longer includes the 280E liability, and management flagged an expectation that the Treasury Department will issue further guidance, including potential retroactive relief, after the rescheduling rulemaking completes.
Read that carefully: over $100 million of cash already sitting in the company's hands is contingent, and $18 million a quarter of interest is accruing against it. This is not in adjusted EBITDA and it is not in the 39% margin. It is a discrete binary that closes with a Treasury document. Alongside it sit the softer unblocks — FinCEN guidance and SAFE Banking — where the CEO described a genuine change in tone with credit card processors: “we are actually a fully Schedule III DEA registered business listed on the NYSE and feel that we should be treated no differently than CVS and or Walgreens.” — Kimberly Rivers, Chief Executive Officer · 2026-11-05 Note that no other reporter in this window plays here. The only adjacent voice, Innovative Industrial Properties, speaks about tenants in regulated cannabis markets — a landlord's abstraction. Nothing in the market-wide keyword set touches this theme at all. Trulieve's entire story is idiosyncratic, which cuts both ways: no sector bid, but no sector crowd either.
Georgia Works. Texas Keeps Waiting.
Georgia is the quarter's genuine acceleration. Patients have gone from 45,000 at the August call to over 60,000, with management now citing 80% growth year to date; dispensaries moved from 6 of the state's 17 to 7 open with the 8th and 9th approved. The CEO was candid: “Georgia has been growing faster, candidly, than what we initially had modeled.” — Kimberly Rivers, Chief Executive Officer · 2026-11-05 The one soft spot is the wholesale pharmacy channel — "almost 20" pharmacies shipping versus the 20 "established relationships" cited last quarter. Flat, not compounding, though 30-plus await licensure and 125-plus have expressed interest.
Texas is where the pattern gets uncomfortable. In August the company was explicit about the trigger: “we will be moving very quickly as soon as we get the green light that our license has converted to final.” — Kimberly Rivers, Chief Executive Officer · 2026-08-07 In November: “We believe that licensure is relatively imminent there... looking forward to launching Texas in 2027.” — Kimberly Rivers, Chief Executive Officer · 2026-11-05 Two consecutive quarters of imminence, now formally budgeted as a 2027 event, and the capex guide rose from $95 million to $105 million largely to pre-build Georgia capacity ahead of demand that has not yet arrived. That is the right bet if the market develops; it is also the kind of spending that turns awkward if it does not.
Florida carries new optionality nobody has priced: a governor's mansion changing hands, which the CEO greeted as “entering kind of a new era in Florida as it relates to the ability to get some of those things done.” — Kimberly Rivers, Chief Executive Officer · 2026-11-05 Against 786 dispensaries and roughly 7,000 hemp points of distribution, small structural fixes — aligning patient certifications with card renewals, telehealth visit extensions — could do more for patient count than a new state entirely.
The Read
This is a company that has genuinely converted itself: Schedule III, DEA-registered, NYSE-listed, roughly net-cash, generating positive free cash flow for six straight reported quarters with $45 million in Q3 against full-year operating cash flow guidance of at least $225 million — while its reported income statement looks like a catastrophe because of a deconsolidation charge. It is also a company whose buyback sat completely unused through the quarter, whose signature 2027 market has slipped a year, and whose most quantified catalyst quietly demoted itself to a footnote. The brand machine and the tax option are real. The growth timeline is not as real as the language suggests.